5种不同方法治疗尿路感染的疗效:一项随机对照试验

2010-09-09 MedSci原创 MedSci原创

MedSci简评:这篇文章研究的内容很简单,但是意义在于能够减少并控制抗生素的滥用。这是潜在的价值。而之所以能够在BMJ上发表,原因在于采取的是随机对照试验,非常严谨。有时未必一定要赶时尚才能发表优秀的文章,关键在于文章的结果是不是可信,是不是对后来读者具有参考价值。 Effectiveness of five different approaches in management of urin

MedSci简评:这篇文章研究的内容很简单,但是意义在于能够减少并控制抗生素的滥用。这是潜在的价值。而之所以能够在BMJ上发表,原因在于采取的是随机对照试验,非常严谨。有时未必一定要赶时尚才能发表优秀的文章,关键在于文章的结果是不是可信,是不是对后来读者具有参考价值。

Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial

Little P, Moore MV, Turner S 2010/8/19 14:02:24
BMJ. 2010 Feb 5;340:c199

免费全文链接: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817051/?tool=pubmed

免费PDF文件下载: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817051/pdf/bmj.c199.pdf

Abstract

OBJECTIVE: To assess the impact of different management strategies in urinary tract infections.

DESIGN: Randomised controlled trial.

SETTING: Primary care.

PARTICIPANTS: 309 non-pregnant women aged 18-70 presenting with suspected urinary tract infection.

INTERVENTION: Patients were randomised to five management approaches: empirical antibiotics; empirical delayed (by 48 hours) antibiotics; or targeted antibiotics based on a symptom score (two or more of urine cloudiness, urine smell, nocturia, or dysuria), a dipstick result (nitrite or both leucocytes and blood), or a positive result on midstream urine analysis. Self help advice was controlled in each group.

MAIN OUTCOME MEASURES: Symptom severity (days 2 to 4) and duration, and use of antibiotics.

RESULTS: Patients had 3.5 days of moderately bad symptoms if they took antibiotics immediately. There were no significant differences in duration or severity of symptoms (mean frequency of symptoms on a 0 to 6 scale: immediate antibiotics 2.15, midstream urine 2.08, dipstick 1.74, symptom score 1.77, delayed antibiotics 2.11; likelihood ratio test for the five groups P=0.177). There were differences in antibiotic use (immediate antibiotics 97%, midstream urine 81%, dipstick 80%, symptom score 90%, delayed antibiotics 77%; P=0.011) and in sending midstream urine samples (immediate antibiotics 23%, midstream urine 89%, dipstick 36%, symptom score 33%, delayed antibiotics 15%; P<0.001). Patients who waited at least 48 hours to start taking antibiotics reconsulted less (hazard ratio 0.57 (95% confidence interval 0.36 to 0.89), P=0.014) but on average had symptoms for 37% longer than those taking immediate antibiotics (incident rate ratio 1.37 (1.11 to 1.68), P=0.003), particularly the midstream urine group (73% longer, 22% to 140%; none of the other groups had more than 22% longer duration).

CONCLUSION: All management strategies achieve similar symptom control. There is no advantage in routinely sending midstream urine samples for testing, and antibiotics targeted with dipstick tests with a delayed prescription as backup, or empirical delayed prescription, can help to reduce antibiotic use. STUDY REGISTRATION: National Research Register N0484094184 ISRCTN: 03525333.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775242, encodeId=71d11e752429e, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 17 20:59:00 CST 2010, time=2010-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765, encodeId=90611e65d2, content=very good <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d926740, createdName=zhangxuhui7576, createdTime=Tue Nov 02 23:37:00 CST 2010, time=2010-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987150, encodeId=93ab198e15013, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Oct 13 16:59:00 CST 2010, time=2010-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296140, encodeId=4bec1296140ea, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Sep 11 05:59:00 CST 2010, time=2010-09-11, status=1, ipAttribution=)]
    2010-09-17 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775242, encodeId=71d11e752429e, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 17 20:59:00 CST 2010, time=2010-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765, encodeId=90611e65d2, content=very good <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d926740, createdName=zhangxuhui7576, createdTime=Tue Nov 02 23:37:00 CST 2010, time=2010-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987150, encodeId=93ab198e15013, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Oct 13 16:59:00 CST 2010, time=2010-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296140, encodeId=4bec1296140ea, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Sep 11 05:59:00 CST 2010, time=2010-09-11, status=1, ipAttribution=)]
    2010-11-02 zhangxuhui7576

    very good

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1775242, encodeId=71d11e752429e, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 17 20:59:00 CST 2010, time=2010-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765, encodeId=90611e65d2, content=very good <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d926740, createdName=zhangxuhui7576, createdTime=Tue Nov 02 23:37:00 CST 2010, time=2010-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987150, encodeId=93ab198e15013, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Oct 13 16:59:00 CST 2010, time=2010-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296140, encodeId=4bec1296140ea, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Sep 11 05:59:00 CST 2010, time=2010-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775242, encodeId=71d11e752429e, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 17 20:59:00 CST 2010, time=2010-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765, encodeId=90611e65d2, content=very good <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d926740, createdName=zhangxuhui7576, createdTime=Tue Nov 02 23:37:00 CST 2010, time=2010-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987150, encodeId=93ab198e15013, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Oct 13 16:59:00 CST 2010, time=2010-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296140, encodeId=4bec1296140ea, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Sep 11 05:59:00 CST 2010, time=2010-09-11, status=1, ipAttribution=)]